Selected Demographic and Clinical Information for Patients Included in Analysis
| Parameter | Data |
|---|---|
| Age (y) | 71.5 (66.8–72.0) |
| Caucasian race | 100% |
| PSA (ng/mL) | |
| PET1 | 24.0 (12.1–47.1) |
| PET2 | 11.0 (6.1–27.0) |
| Interval between PET1 and PET2 (d) | 84 (70–91.5) |
| Therapy initiated | |
| Abiraterone | 88% |
| Enzalutamide | 13% |
Qualitative data are percentages based on 16-patient sample size; continuous data are median and IQR. Mention of race is relevant in the context of prostate cancer because Black patients tend to have more aggressive underlying biology of disease and less access to health care in the United States.